Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension

• Hoofdauteurs: Alexandra B. Kimball (Auteur), Thomas Luger (Auteur), Alice Gottlieb (Auteur), Luis Puig (Auteur), Roland Kaufmann (Auteur), Russel Burge (Auteur), Chen-Yen Lin (Auteur), Gil Yosipovitch (Auteur)
• Formaat: Boek
• Gepubliceerd in: Medical Journals Sweden, 2017-10-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Itching is a prevalent plaque psoriasis symptom. Ixekizumab, an IL-17A antagonist, has demonstrated rapid, significant improvements in itch severity over 12 weeks in Phase III psoriasis trials (UNCOVER-1, UNCOVER-2). We assessed the long-term (through 60 weeks) effect of ixekizumab maintenance thera...